New cell therapy trial targets Hard-to-Treat stage IV cancers
NCT ID NCT06296056
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This early-phase trial tested a combination of immune cells (cellular immunotherapy) in 9 people with stage IV solid tumors that had not responded to standard treatments. The main goal was to check safety and side effects, while also looking at whether the therapy could shrink tumors. The study was completed, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul Hospital
Ulaanbaatar, Mongolia
Conditions
Explore the condition pages connected to this study.